We are live on
!
Find out more
Immunic
IMUX
IMUX
58 hedge funds and large institutions have $81.3M invested in Immunic in 2018 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
24% more capital invested
Capital invested by funds: $65.6M → $81.3M (+$15.7M)
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 57 → 58 (+1)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0.01% more ownership
Funds ownership: 0.07% → 0.07% (+0.01%)
86% less call options, than puts
Call options by funds: $114K | Put options by funds: $830K
Holders
58
Holders Change
+1
Holders Change %
+1.75%
% of All Funds
1.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
16
Reduced
15
Closed
12
Calls
$114K
Puts
$830K
Net Calls
-$716K
Net Calls Change
-$276K
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.22M |
| 2 |
Millennium Management
New York
|
+$941K |
| 3 |
Goldman Sachs
New York
|
+$893K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$757K |
| 5 |
AG
Artal Group
Luxembourg
|
+$716K |
